Literature DB >> 12231583

Heparin dose during percutaneous coronary intervention: how low dare we go?

G Niccoli1, A P Banning.   

Abstract

Despite dramatic advances in percutaneous coronary intervention, including coronary stents and potent antiplatelet agents, unfractionated heparin remains the standard procedural anticoagulant. Tradition and habit may have considerable influence over dose selection. A review of the role and dosage of heparin during PCI appears to be overdue

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12231583      PMCID： PMC1767377          DOI： 10.1136/heart.88.4.331

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  53 in total

Review 1.  Anticoagulation requirements for coronary interventions and the role of low molecular weight heparins.

Authors:  C L Grines
Journal:  J Invasive Cardiol       Date:  1999-06       Impact factor: 2.022

Review 2.  Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.

Authors:  E R Bates
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

Review 3.  Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.

Authors:  J Hirsh; S S Anand; J L Halperin; V Fuster
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

4.  Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.

Authors:  J A Ambrose; R Doss; J M Geagea; M C Hawkey; S Duvuri; K Giedd; A Dominguez; J Coppola; T H Nguyen; V Palla; R S Barua; D C Saha
Journal:  Am J Cardiol       Date:  2001-05-15       Impact factor: 2.778

Review 5.  The search for replacements for unfractionated heparin.

Authors:  E M Antman
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

6.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Authors: 
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

7.  Induction of the acute-phase reaction increases heparin-binding proteins in plasma.

Authors:  E Young; T J Podor; T Venner; J Hirsh
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-08       Impact factor: 8.311

Review 8.  Importance of antithrombin therapy during coronary angioplasty.

Authors:  J H Chesebro; L Badimon; V Fuster
Journal:  J Am Coll Cardiol       Date:  1991-05       Impact factor: 24.094

Review 9.  Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations.

Authors:  G F Pineo; R D Hull
Journal:  Med Clin North Am       Date:  1998-05       Impact factor: 5.456

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
View more
  3 in total

1.  Activated clotting time level with weight based heparin dosing during percutaneous coronary intervention and its determinant factors.

Authors:  Majid Soleimannejad; Naser Aslanabadi; Bahram Sohrabi; Morteza Shamshirgaran; Ahmad Separham; Babak Kazemi; Ebrahim Khayati Shal; Reza Madadi; Hamidreza Shirzadi; Hoda Azizi; Samad Ghaffari
Journal:  J Cardiovasc Thorac Res       Date:  2014-06-30

2.  Heparinase treatment of heparin-contaminated plasma from coronary artery bypass grafting patients enables reliable quantification of microRNAs.

Authors:  Kirill Kondratov; Dmitry Kurapeev; Maxim Popov; Marina Sidorova; Sarkis Minasian; Michael Galagudza; Anna Kostareva; Anton Fedorov
Journal:  Biomol Detect Quantif       Date:  2016-04-08

3.  Fatal Ovarian Hemorrhage Associated With Anticoagulation Therapy in a Yucatan Mini-Pig Following Venous Stent Implantation.

Authors:  Sophie Boorman; Hope Douglas; Bernd Driessen; Matthew J Gillespie; Thomas P Schaer
Journal:  Front Vet Sci       Date:  2020-01-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.